Home » Market News » DirectorsTalk Highlights » Skin’s Immune ‘Alarm’ May Explain Light-Induced Rashes in Lupus Patients
Immupharma Plc

Skin’s Immune ‘Alarm’ May Explain Light-Induced Rashes in Lupus Patients

This is the unfortunate reality for many people with lupus. Up to 60 percent of patients with the autoimmune disease have sensitivity to ultraviolet light, a condition called photosensitivity. It can result in skin inflammation or a flare-up of a wide range of lupus symptoms, for example joint pain and fatigue.

For some patients, even the light of a photocopier is enough to trigger the disease’s characteristic angry red rash.

ImmuPharma PLC (LON:IMM) is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.